X
Dec 07, 2020 08:59 PM (GMT+8) · EqualOcean
According to kechuangboard daily on the 7th, the reporter learned from Fuhong Hanlin (2696. HK) that its independently developed and produced adamumab hlx03 (trade name: handanyuan) has been approved by the State Drug Administration for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis. At present, the treatment of adalimumab for the above three indications has been included in the national medical insurance catalogue, which belongs to the payment scope of basic medical insurance fund. Fuhong Hanlin has reached a commercialization agreement with Wanbang pharmaceutical, a subsidiary of Fosun Pharmaceutical, to authorize the latter to carry out commercial operation.

This text is a result of machine translation.